Sorafenib-RT Treatment for Liver Metastasis (SLIM)
Status:
Completed
Trial end date:
2020-09-08
Target enrollment:
Participant gender:
Summary
Cancers that have spread to the liver from the primary cancer location (liver metastases)
that cannot be removed surgically (unresectable) can be treated with chemotherapy and/or
radiation therapy. Previous research has shown that tumours often have abnormal blood vessels
that may reduce the effect of radiation therapy. New drugs, known as "anti-angiogenic" drugs
have been shown in animal and human studies to damage or change tumour blood vessels in ways
that may make tumors more sensitive to radiation treatment. 32- 44 Patients diagnosed with
unresectable liver metastasis will be invited to take part in this study. The purpose of this
study is to investigate the use of a new anti-angiogenic drug called Sorafenib, in
combination radiation therapy and chemotherapy. The study will test how effective the new
treatment is, the side effects associated with the new treatment, and to help establish safe
dosages of the study medication.